Life Sciences Archive » August, 2018

Life Sciences - August, 2018

314 articles

• Stryker Must Face Suit Over Rep's Alleged Assault Of Nurse
• Pharma Cases To Watch In 2018's Home Stretch
• DOJ, MassBio Back Helsinn In High Court On-Sale Bar Fight
• After High Court Loss, Cos. Say Price Fix Hit Still Wrong
• Ex-Glaxo Scientist Cops To IP Theft For Chinese Pharma Co.
• OvaScience Director Compensation Suit Settled In Del.
• Dealmakers Expect 'Crowded' IPO Calendar After Labor Day
• New Pass-Through Deduction Will Pass Over Many Lawyers
• Health Hires: Quinn Emanuel, Manatt, Strategic, Perkins Coie
• Sexual Enhancement Cos. Barred From Selling Illicit Drugs
• Carlton Fields Nabs Entertainment Litigator For LA Office
• Mallinckrodt Investors Defend False Statements Suit
• How Reckless Judicial Impeachments Threaten Rule Of Law
• Judging A Book: Fogel Reviews 'Good Judgment'
• Taxation With Representation: Sidley, Skadden, Norton
• Adocia Arbitration Claim Against Eli Lilly Climbs To $1.8B
• Medtronic Can't Nix Shareholder Suit Over Merger In Ireland
• DOJ Says It Can Prove Novartis Dinners Were Kickbacks
• Bayer, Janssen Win Another Xarelto Injury Trial In Philly
• Purdue Ends OxyContin Patent Suit With $62M Payout
• Calif. Gets PhRMA's Challenge To Drug Pricing Law Axed
• Enviro Sues Chemours, Alleging NC Water Contamination
• 10 Ways To Prevent E-Discovery Woes
• 3D-Printed Pharmaceuticals? Don't Try This At Home
• The Challenges Of Valuing Litigation-Driven Equities
• Skadden, Simpson Thacher Guide $1.4B Stryker-K2M Deal
• Travel Act Gets Mileage In Health Care Cases
• J&J Hip Implant Plaintiffs Get $245M Judgment After Trial
• Fed. Circ. Impeding Biopharma Innovation, Justices Told
• Allergan, Shire Spar Over Pfizer-J&J Antitrust Ruling
• 4 Health Care Cos. Escape Mass. FCA Suit Over Blood Tests
• 11th Circ. Says Mesh Sling Suit's Injury Notice Beat Time Limit
• Wilson Sonsini Nabs Veteran Hogan Lovells Corporate Atty
• Why Courts Should Apply Escobar In Criminal Cases
• Baker Donelson Nabs IP Atty From Fox Rothschild
• Atty's Restitution Reduced By $12.2M In Stock Scheme
• FDA Warning Wire: Estrogen Drug Promo, Zimmer Quagmire
• Sessions Aide Confirmed To Lead DOJ Civil Division
• 3rd Circ. Revives Heart Monitor Co.'s BCBS Antitrust Suit
• Pfizer Attacks 'False' Biosimilar Info, Urges FDA Action
• Galderma Wins On 5 Patents In Generic Oracea Suit
• Shipping Co. Can't Nix Suit Over Kickback Payments
• McKesson Workers' Narrowed OT Class Gets Conditional Cert.
• CVS Ducks Sentry Data's Antitrust Claim, For Now
• Outset Medical Will Bolster Dialysis Biz With $132M Fund
• Teva Can't Move IP Suits Over Opioid Treatment Drug To Del.
• On-Sale Bar Doesn't Cover Secret Prior Art, Justices Told
• Invisalign Maker Cornered Mouth Scanner Market, Rival Says
• 4 Key Components To New Firm Partnership Agreements
• Par Wants Bulk Vasopressin Compounding Nixed; FDA Agrees
• Hospira Can't Void Amgen's $70M Biosimilar Patent Win
• Deficient Drug Trial Caused Stock Drop, Ampio Investor Says
• Ken Starr Joins Lanier Firm, Returning To Private Practice
• Alvogen Wins Generic Zohydro Case Over Pernix Patents
• Docs' Attys Win $5.7M From $13.5M Botox Pricing Deal
• 1st Circ. Says Challenge To Rx Eyedropper Size Preempted
• Harbour BioMed Lands $85M In Series B Funding
• Gleevec Buyers Ask For Time To Mull 1st Circ. Rehearing Bid
• Amgen Shows New Patents Can Affect Prior BPCIA Litigation
• Goodwin Procter Adds Ex-DLA Piper Life Sciences Pro
• Open The Federal Courthouses
• Woman's J&J Talc Bottle Contained Asbestos, Jury Hears
• Walmart Says Opioid FCA Suit Doesn't Show Medicare Fraud
• Full Fed. Circ. Won't Rethink Upholding UCB's Vimpat Patent
• Ancestry Gets 23andMe Patent Killed, But TM Claims Survive
• Ex-Insys Execs Press Gov't For RICO Indictment Details
• 7th Circ. Focuses On Impossibility Preemption In Dolin V. GSK
• Warner, Lowe's Can't Dodge Benefits Suit, HIV Patients Say
• China Biologic Rejects $3.9B Takeover Bid Led By Ex-CEO
• Incorporating Docs By Reference: New 9th Circ. Law Is Flawed
• FTC Scores Separate Trial In AndroGel Antitrust Row
• Eli Lilly To Face Remaining Claims In Father's Birth Defect Suit
• Investors Need New Leader For Biotech IPO Suit, Judge Says
• Calif. High Court Will Hear Niaspan Pay-For-Delay Appeal
• VC-Backed Bay Area Biotech Files Plans For $80M IPO
• Ex-Shkreli Atty Taps Williams Heavy Hitter For Appeal
• No Clear Winner In $4.3B Akorn Deal Row: Vice Chancellor
• Monsanto Faces 8,000 Glyphosate Suits, Bayer CEO Says
• DePuy Hit With $8.2M Verdict In Implant Patent Fight
• DOJ Urges Toss Of FCA Suit Targeting Opioid Sellers
• Warning Label Suit Over J&J Talc To Stay In Fed. Court
• On-Sale Bar Ruling 'Profoundly Erroneous,' High Court Told
• Don't Allow Patents On Old Ideas, Nonprofits Urge Justices
• Payors Share Some Responsibility For The Opioid Epidemic
• Foley Gardere Snags Baker McKenzie Biotech IP Specialist
• Brexit: Bracing For A No-Deal Scenario
• Trump's Latest China Tariffs Take Effect As Beijing Retaliates
• Bids To Bounce $1B Herbalife RICO Class Action Fall Short
• Morgan Lewis Continues IP Expansion, Adds 9-Partner Team
• Orexigen Says McKesson Can't Nab $7M In Debt Setoff Fight
• CBS Opioid Segments Didn't Defame Pharmacist, Judge Rules
• Pfizer Chips Away At State Claims In Lipitor Antitrust MDL
• Opioid Cos. Slammed With More Suits Over High Health Costs
• PTAB Wrongly Axed Part Of Invisalign Patent, Fed. Circ. Says
• NJ County Aims To Kick McKesson Opioid Suit To State Court
• Reed Smith Atty's Widow Loses $3M GSK Verdict On Appeal
• GSK Can Keep Docs Private In Lamictal Antitrust Suit
• Fed. Circ. Clarifies Enablement Requirement In LED Case
• J&J, Supplier Defend Talc In Latest Trial On Asbestos Link
• 9th Circ. Opinion Could Spark More Securities Settlements
• Contact Lens Makers Look To Dispose Of Pricing Plot Suit
• Attys Relaunch Bid For 'Opioid Babies' Track In MDL
• Novartis Beats Gleevec Monopolization Suit At 1st Circ.
• Orlando Health Hit With $100M Defamation Suit By Fired MD
• Sherwin-Williams Ducks Class Action Over NJ Pollution
• Galena Investors' Stock-Drop Suit Gets Axed, For Now
• FDA Warning Wire: Drug Spec Checks Get Wrecked
• Deals Rumor Mill: GSK, Amaysim, Cepsa
• Omnicare's $1.3M Deal In Credit Reporting Suit OK'd
• Feds Ordered To Hand Over Insys Docs From 10 Agencies
• FTC Pushes For Separate Trial In AndroGel Antitrust Suit
• NJ Justices Centralize Taxotere Hair-Loss Suits
• Internal Docs Led To Couple's $117M Win In J&J Talc Case
• FDA Focus: What Mayer Brown's Practice Chair Is Watching
• In SDNY, Indicting Politicians Is The New Black
• 'High Availability' — A Key Term In Law Firm IT Strategy
• Woman Used Asbestos-Laden J&J Talc, Jury Told In New Trial
• Allergan, Tribe Want PTAB Immunity Denial Reheard En Banc
• Mylan, Pfizer Barely Put Dent In EpiPen Antitrust MDL
• China Biologic's Former CEO Leads $3.9B Takeover Bid
• SEC Ends Bribery Probe Into Chinese Vaccine Co.
• Insys Execs Say Expert Witness Switched Sides
• CVS, Rite Aid Hit AbbVie With Antitrust Suit Over AndroGel
• Stryker's Coverage Claims Over Knee Implants Deemed Viable
• 7th Circ. Gives Law Firm 2nd Shot At Suing Lupin For Fees
• UK Online Fashion Retailer Joins Wave Of IPO Filings
• California Diaper Co. Can't Dodge Massachusetts FCA Suit
• NJ Justices Centralize Zostavax Suits Against Merck
• The 'Post-Fact' Jury In The 'Fake News' Era
• FDA Biosimilars Plan Draws From Experience With Generics
• Latham Fortifies Star IP Trial Team With WilmerHale Atty
• Fixing Rule 41: A Balanced Approach To Voluntary Dismissal
• DOJ's New Policy On FCA Dismissals Highlights Circuit Split
• Client's Benicar Trial Bill Shouldn't 'Scare Off' Firm: Judge
• Promega Gets Damages Appeal All Wrong, Life Tech Says
• Split Fed. Circ. Says Family Can't Get Vaccine Act Relief
• Nationwide Ban OK For Trump Birth Control Rules, States Say
• Lincare Inks $5M FCA Kickbacks Deal Over Waived Copays
• Ex-Lannett Execs Face Derivative Suit Over Antitrust Probes
• Setbacks Shake Up Fla.'s Medical Marijuana Rollout
• Health Hires: Dorsey & Whitney, DLA Piper, Epstein Becker
• Impax Says Opana Deal Didn't Delay Competition
• Ex-Katten Atty Gets 18 Months In Prison For Shkreli Fraud
• Peering Behind The Peer Review Curtain
• Taxation With Representation: Akin Gump, Wachtell, Kirkland
• Judging A Book: Lipez Reviews 'Last Great Colonial Lawyer'
• Will Law Schools Start Counting 'Generation ADA'?
• Ancestry.com Says 23andMe DNA Patent Invalid Under Alice
• TKK Symphony Prices $220M IPO To Pursue China Deal
• 8th Circ. Voids Tax Court Ruling In $1.36B Medtronic Case
• Fed. Circ. Upholds Duties On Compression Garments
• FDA Clears First EpiPen Generic, Made By Teva
• DEA To Cut Drugmaker Production Of Most-Abused Opioids
• Keryx Shouldn't Get 2nd Chance To Ax Stock Suit, Court Told
• 3rd Circ. Won't Revive Allergan Medicaid Rebate Suit
• SEC Nabs 2 Judgments In NY Rep. Insider Trading Case
• Novo Nordisk Can't Dodge Shareholder Suit In NJ
• Monsanto's $289M Roundup Loss Ripples Across Industries
• Athenex Pharma OK'd To Intervene In Par Suit Against FDA
• Buchalter Adds 2 Attys To Corp., Litigation Groups In LA
• NJ High Court Centralizes Some J&J Hernia Mesh Lawsuits
• Rising Star: Winston & Strawn's Kurt Mathas
• A Chat With Ogletree Knowledge Chief Patrick DiDomenico
• 9th Circ. Criticism Of Judicial Notice Trend Is Significant
• Ex-Katten Atty Loses Bid To Dodge Shkreli Fraud Charges
• Out-Of-State Drugs Can Be Taxed, Minn. High Court Rules
• Diagnostics Co. Investors Fight Bid To Nix Stock-Drop Suit
• Masimo, Dominion Settle Suit Over Blood Monitoring Patent
• Blackstone Pours $400M Into Chinese Pharma Co.
• Davis Polk, Cooley Steer ViewRay's $150M Follow-On Offering
• Cabot Inks $1.6B Cash-And-Stock Deal For Chemicals Co.
• Makah Indian Tribe Hits Pharma Cos. With Opioid Crisis Suit
• Rising Star: Sidley Austin's Benjamin M. Mundel
• Ensnarement — A 2nd Bite At The Noninfringement Apple
• How One Firm Moved The Needle On Disability Inclusion
• Deals Rumor Mill: Carlyle, CIE Automotive, Sinochem
• PTAB Shuts Down Hologic Challenges To HIV Detection Patent
• FDA Warning Wire: Concern At Apotex Plant, Poppy Seed Tea
• Speaker Program Payments Weren't Kickbacks, Teva Says
• Fed. Circ. Lets Stand Vanda Ruling That Led To USPTO Memo
• NY Joins Flood Of Opioid Suits Against Purdue Pharma
• DOJ Taps Ex-AG Mukasey To Monitor Bayer-Monsanto Deal
• Time Expired On Defective Zimmer Hip Implant Claim: Judge
• Drug Kickback Suit Against Eli Lilly Dismissed For Now
• PTAB Scraps 2 Aker BioMarine Krill Oil Patents
• Rising Star: Paul Hastings' Isaac Ashkenazi
• Distributors Expose Health, Life Sci Cos. To FCPA Risks
• Interview Essentials For Attorneys On The Move
• 1 NASA Small-Biz Contract, 1 Giant Leap For Plantkind
• Investors Secure Class Cert. In Biotech Stock-Drop Case
• David Boies On How Dyslexia Shaped His Practice
• Relator Dismissed From GE Healthcare False Claims Act Suit
• BigLaw's Mental Health Stigma Shows Signs Of Fading
• States Push Back Against Dismissal Bids In Opioid MDL
• After 'Untenable' IP Case, Judge Says MoFo Is Owed Fees
• ActiveCare Gets Nods On DIP Financing, Auction Plans
• 5 State AGs Argue Against $62B Bayer-Monsanto Deal
• Aralez Gets OK To Tap $5M DIP, Must Produce Budget Info
• Opioid MDL Bellwether Trial Postponed 6 Months
• FTC Overstepped In Shire FDA Petitions Case, 3rd Circ. Told
• 9th Circ. Rips Judicial Notice Trend In Securities Suits
• Fed. Circ. Wrong On HIV Drug Patent Challenge, Justices Hear
• Risk Mitigation Strategies For Gene Therapy Developers
• Warner Media Wants Out Of Benefits Suit Over HIV/AIDS Meds
• Rising Star: Fish & Richardson's Joseph Warden
• Clerking For Ginsburg
• Gaining Access: Disabled Lawyers Share Their Stories
• How The Legal Industry Lets Down Lawyers With Disabilities
• Deals Rumor Mill: Frontier-Suzhou, VF Corp., SIG Combibloc
• J&J Can't Ax Pfizer Antitrust Suit Over Remicade Biosimilar
• Insurer Won't Cover Bias Suit Over Employee's Breast Cancer
• Pending Patent's Inventor Can't Be Disputed, Fed. Circ. Says
• Fla. Medical Provider To Pay $2.2M To End Kickback Claims
• Monsanto Owes $289M In Landmark Roundup Cancer Trial
• Celator Insider Trading Schemers Spared Prison Time
• FDA Focus: What Lowenstein's Practice Chair Is Watching
• Merus Asks High Court To Bat Down Mouse Patent Appeal
• Aralez Sheds Assets For $250M As Bankruptcy Cases Begin
• UK Biotech Co. Closes Latest Funding Round With $84M
• Kavanaugh On Attorney-Client Privilege — 3 Takeaways
• Federal Law Both Sword And Shield In Cannabis Litigation
• Rising Star: Latham & Watkins' Brian Cuneo
• Clerking For Ginsburg: 3 Surprises
• 2nd Circ. Strict On FCA First-To-File Bar In Allergan Case
• Atty Fees In $5M Chinese Award Row Must Also Be Arbitrated
• Mesa Air Group Leads 3 IPOs Raising $260M Combined
• UK Antitrust Watchdog Can Withhold Warrant Info, Court Says
• Lupin Accused Of Hiring Older Sales Pros To Poach Clients
• J&J Hip Implant Plaintiffs Seek $246M Judgment After Trial
• Testing Mandate Is Straining California Cannabis Cos.
• Clerking For Ginsburg: A Superhero Supreme
• Covington Guides Emergent's $270M Vaccine Biz Buy
• Judge Slashes $15M From Pelvic Mesh Verdict Against J&J
• Skadden Leads Chinese Biotech Firm's $903M Hong Kong IPO
• Judge Probes Mental State In Dr. Reddy's Manufacturing Suit
• Lift Block On Trump Birth Control Rules, Gov't Tells 9th Circ.
• Mendocino County Pot Tax Upheld By Calif. Appeals Court
• PTAB Rightly Axed Alcon Eye Drop Patent, Fed. Circ. Says
• J&J Urges Pa. Appeals Court To Undo $2.5M Risperdal Verdict
• TIAA Says It Should Be Only Lead Plaintiff In Valeant Suit
• NJ Woman's Mesh Case Doesn't Belong In Pa., Ethicon Says
• Blockchains: A Better Tool For Supply Chain Management
• Where The Gibson Taxpayers Went Wrong
• Insys To Pay $150M To End DOJ Scrutiny Of Opioid-Rx Bribes
• Why Bristol-Myers Applies To Absent Class Members: Part 3
• Biotech Executive Convicted Of Fraud, Lying To Feds
• Clerking For Ginsburg: 4 RBG Lessons On Having It All
• On-Sale Bar Questions Leading Up To Helsinn At High Court
• China Strikes Back At US Over Latest IP Tariff Escalation
• NY Rep. Chris Collins, Family Charged With Insider Trading
• Monsanto Owes $412M For Roundup 'Reckoning,' Jury Hears
• Fed. Circ. Created Disclosure 'Anarchy,' Amgen Tells Justices
• AstraZeneca Settles Texas Medicaid Fraud Suits For $110M
• AgaMatrix Gets $1.3M Fees From Dexcom's Failed IP Suit
• KKR-Backed Clinical Trials Co. Prices $660M Stock Offering
• Fortuity Rules May Incite Coverage Row Over Opioid Lawsuits
• Tackling Digital Class Notice With Rule 23 Changes
• Scientist Ducks Prison In Medical Device Bribery Scheme
• Why Bristol-Myers Applies To Absent Class Members: Part 2
• Mylan Wants Investors' 'Copycat' EpiPen Claims Dismissed
• Clerking For Ginsburg: How To Play The Long Game
• Monsanto Faces Punitives Bid As Cancer Trial Nears End
• MMA Fighter's Suit Over Dietary Supplements Limps Forward
• Feds, Biotech CEO Spar Over If Lies Were Crimes Or Flubs
• Fla. Bar Seeks Discipline Against South Fla. IP Atty
• Cherokee Nation Wants Purdue Opioid Row In State Court
• ActiveCare Delays Ch. 11 Auction Plan For Committee Talks
• Biopharma Co. Aridis Launches $28M IPO For Clinical Trials
• Providers Say Don't Kill Hospital Bellwether In Opioid MDL
• 3rd Circ. Gives Biomet New Chance To Access Docs In IP Row
• Dental Cos. Look to Straighten Patent Row In Fed. Circ.
• Humana Hits Generic-Drug Makers With Price-Fixing Claims
• Actavis At 5: Where Pay-For-Delay Litigation Stands
• FDA Rejects Opioid Painkiller For The 4th Time
• Why Bristol-Myers Applies To Absent Class Members: Part 1
• Clerking For Ginsburg: In Pursuit Of Precision
• Time To Remove Patent Barriers To US Drug Manufacturing
• High Court Ruling Can't Help Pfizer 'Win The Day' In Class Suit
• CVS Hits Pfizer With Antitrust Suit Over Lipitor Delay
• JPML Bundles Dozens Of Zostavax Suits In Philadelphia
• ​​​​​​​FTC Can't Block Theoretical Drugmaker Moves, Shire Says
• Ind. Court Tosses Surgery-Privacy Suit Against Stryker
• Ex-Shkreli Atty Claims Companies Can't Be Victims
• PTAB Shoots Down Pfizer's Bid To Review Avastin Patent
• Keryx Wants Auryxia Stock-Drop Suit Reconsidered
• Allergan Sells Dermatology Drugs To Almirall For $650M
• Drugmaker Escapes Stock-Drop Suit Over Opioid Statements
• Juno Investors Reach $24M Deal In Stock-Drop Class Action
• An Upgrade For Expert Evidence Standards In New Jersey
• Genetic Testing Cos. Must Examine Illinois Privacy Law
• Clerking For Ginsburg: My RBG Guide To Judging
• Endo To Pay Texas $13M Over Off-Label Lidoderm Sales
• Bayer, Dow Hit With Polyurethane Price-Fixing Suit
• Otonomy Scores Fed. Circ. Win In Ear Treatment Patent Case
• Allergan Files 3rd-Party Claims Against Pfizer In Opioid MDL
• NJ Accutane Ruling Raises Bar For Expert Witnesses
• Morgan Lewis Adds WilmerHale Partners In Silicon Valley
• It's Prime Time For A Dose Of Reality On Brett Kavanaugh
• Clerking For Ginsburg: 4 Things I Learned
• Merck Can't Sink Cert. In $250M Sex Bias Class Action
• UPDATE: Valeant Says Katten Hires Created Conflict In Drug Patent Suit
• NJ Targets Cos. With Pollution Suits, Some First Since '08
• Opioid MDL Counties Get Partial Info From McKesson Report
• Insider Trader Can't Get Passport Back Ahead Of Sentencing
• Class Attys Want $39M Cut Of $105M Lidoderm Settlement
• NJ Justices Say Unreliable Evidence Kills Accutane MDL
• Top Product Liability Cases Of 2018: Midyear Report
• Valeant Can't Escape RICO Claims In 3 Investor Fraud Suits
• White House Sets Out 2020 R&D Focus For US Agencies
• Benecol Buyers Seek Class Cert. In Trans Fat False Ad Suit
• Grifols To Divest 3 US Plasma Centers As Part Of $286M Deal
• NewLink Looks To Nix Investor Suit Over Cancer Drug, Again
• Strategies For Dealing With US-China Tariffs
• Clerking For Ginsburg: The Equality Lessons